Last reviewed · How we verify
Nanjing NingQi Medicine Science and Technology Co., Ltd. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Changchun marina | Changchun marina | marketed | Anti-arrhythmic | Potassium channels | Cardiovascular | |
| parapl | parapl | marketed | Other | |||
| Danggui-Sini granules | Danggui-Sini granules | phase 3 | Pain Management / Cardiovascular | |||
| Huangqi-Guizhi-Wuwu granules | Huangqi-Guizhi-Wuwu granules | phase 3 | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 2
- Other · 1
- Pain Management / Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- University of British Columbia · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Nanjing NingQi Medicine Science and Technology Co., Ltd.:
- Nanjing NingQi Medicine Science and Technology Co., Ltd. pipeline updates — RSS
- Nanjing NingQi Medicine Science and Technology Co., Ltd. pipeline updates — Atom
- Nanjing NingQi Medicine Science and Technology Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Nanjing NingQi Medicine Science and Technology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nanjing-ningqi-medicine-science-and-technology-co-ltd. Accessed 2026-05-18.